Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
1. A compound represented by Formula Ib:
wherein
q is 0 or 1;
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
one of Z 3 or Z 4 is —NR 2 — and the other of Z 3 or Z 4 is —C(O)—;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
is a single or a double bond;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 5 is selected from the group consisting of hydrogen, acyl, sulfonyl, aminoacyl, oxycarbonyl, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R 9 , —S(O) 2 NR 6 R 9 , —NR 6 R 9 and —OR 9 ; and
R 9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; and
further wherein each alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl described above for R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 can be optionally substituted with from 1 to 3 R 10 ,
wherein each R 10 is independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thioxo, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, sulfonyl, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, —OS(O) 2 -alkyl, —OS(O) 2 -aryl, —OS(O) 2 -heteroaryl, —OS(O) 2 -heterocyclic, —OSO 2 —NR 40 R 40 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 -aryl, —NR 40 S(O) 2 —NR 40 -heteroaryl, and —NR 40 S(O) 2 —NR 40 -heterocyclic, where each R 40 is independently selected from the group consisting of hydrogen or alkyl; and further wherein each alkyl, alkoxy, aryl, aryloxy, aryloxyaryl, cycloalkyl, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, or heterocyclyloxy may be additionally substituted with from 1-3 substituents independently alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen;
or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer or prodrug thereof.
2. The compound of claim 1 , represented by Formula IIIa:
wherein
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
is a single or a double bond;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R 9 , —S(O) 2 NR 6 R 9 , —NR 6 R 9 and —OR 9 ; and
R 9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; and
further wherein each alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl described above for R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 can be optionally substituted with from 1 to 3 R 10 ,
wherein each R 10 is independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thioxo, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, sulfonyl, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, —OS(O) 2 -alkyl, —OS(O) 2 -aryl, —OS(O) 2 -heteroaryl, —OS(O) 2 -heterocyclic, —OSO 2 —NR 40 R 40 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 -aryl, —NR 40 S(O) 2 —NR 40 -heteroaryl, and —NR 40 S(O) 2 —NR 40 -heterocyclic, where each R 40 is independently hydrogen or alkyl; and further wherein each alkyl, alkoxy, aryl, aryloxy, aryloxyaryl, cycloalkyl, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, or heterocyclyloxy may be additionally substituted with from 1-3 substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen;
or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer or prodrug thereof.
3. The compound of claim 1 , represented by Formula IIIb:
wherein
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
is a single or a double bond;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R 9 , —S(O) 2 NR 6 R 9 , —NR 6 R 9 and —OR 9 ; and
R 9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; and
further wherein each alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl described above for R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 can be optionally substituted with from 1 to 3 R 10 ,
wherein each R 10 is independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thioxo, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, sulfonyl, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, —OS(O) 2 -alkyl, —OS(O) 2 -aryl, —OS(O) 2 -heteroaryl, —OS(O) 2 -heterocyclic, —OSO 2 —NR 40 R 40 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 -aryl, —NR 40 S(O) 2 —NR 40 -heteroaryl, and —NR 40 S(O) 2 —NR 40 -heterocyclic, where each R 40 is independently hydrogen or alkyl; and further wherein each alkyl, alkoxy, aryl, aryloxy, aryloxyaryl, cycloalkyl, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, or heterocyclyloxy may be additionally substituted with from 1-3 substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen;
or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer or prodrug thereof.
4. The compound of claim 1 , wherein
alk is optionally substituted C 1 -C 6 alkylene;
W 1 is —C(O)OR 9 , —NR 6 C(O)R 9 , —NR 6 C(O)NR 6 R 9 , or —NR 6 S(O) 2 R 9 ; and
each R 6 is independently hydrogen or alkyl.
5. The compound of claim 1 , wherein
alk is optionally substituted C 1 -C 6 alkylene;
W 1 is R 9 ; and
R 6 is hydrogen or alkyl.
6. The compound of claim 1 , wherein q is 0.
7. The compound of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, cyano, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl.
8. The compound of claim 3 , wherein Z 3 is —NR 2 —, and Z 4 is —C(O)—.
9. The compound of claim 3 , wherein Z 3 is, —C(O)—, and Z 4 is —NR 2 —.
10. The compound of claim 3 , wherein R 2 is selected from the group consisting of hydrogen, and optionally substituted alkyl.
11. The compound of claim 1 , wherein is a single bond.
12. The compound of claim 1 , wherein is a double bond.
13. The compound of claim 3 , wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl.
14. The compound of claim 3 , wherein Y is —NR 6 —, and R 6 is hydrogen or optionally substituted alkyl.
15. The compound of claim 3 , wherein Y is —O—.
16. The compound of claim 3 , wherein R 5 and R 6 are each independently selected from the group consisting of hydrogen, and optionally substituted alkyl.
17. The compound of claim 3 , wherein R 7 and R 8 are each independently selected from the group consisting of hydrogen, and optionally substituted alkyl; or R 7 and R 8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl.
18. The compound of claim 3 , wherein W is R 9 or —C(O)OR 9 .
19. The compound of claim 3 , wherein R 9 is hydrogen.
20. The compound of claim 3 , wherein
q is 0;
R 1 is selected from the group consisting of hydrogen, cyano, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
R 5 is selected from the group consisting of hydrogen, and optionally substituted alkyl; and
R 6 , when present, is selected from the group consisting of hydrogen, and optionally substituted alkyl.
21. The compound of claim 3 , wherein
q is 0;
R 1 is selected from the group consisting of hydrogen, cyano, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 2 is substituted alkyl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
Y is —O— or —NR 6 —; and
R 5 and R 6 are hydrogen.
22. The compound of claim 3 , wherein
q is 0;
R 1 is selected from the group consisting of hydrogen, cyano, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 2 is substituted alkyl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
Y is —O— or —NR 6 —;
R 5 and R 6 are hydrogen;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, and optionally substituted alkyl; or R 7 and R 8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl; and
W is R 9 or —C(O)OR 9 .
23. The compound of claim 3 , wherein
q is 0;
R 1 is selected from the group consisting of hydrogen, cyano, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 2 is substituted alkyl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
Y is —O— or —NR 6 —;
R 5 and R 6 are hydrogen;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl; R 7 and R 8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl;
W is —C(O)OR 9 ; and
R 9 is hydrogen.
24. A compound selected from the group consisting of [(6-benzyl-4-hydroxy-5-oxo-5,6-dihydro-[2,6]naphthyridine-3-carbonyl)-amino]-acetic acid; 3-[(6-benzyl-4-hydroxy-5-oxo-5,6-dihydro-[2,6]naphthyridine-3-carbonyl)-amino]-propionic acid; [(6-benzyl-1-cyano-4-hydroxy-5-oxo-5,6-dihydro-[2,6]naphthyridine-3-carbonyl)-amino]-acetic acid; [(1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-acetic acid; 3-[(1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-propionic acid; 3-[(1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-2,2-dimethyl-propionic acid; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (pyridin-4-ylmethyl)-amide; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid methylamide; 1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid methylamide; {[1-benzyl-5-(5-fluoro-pyridin-3-yl)-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl]-amino}-acetic acid; 3-{[1-benzyl-5-(5-fluoro-pyridin-3-yl)-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl]-amino}-propionic acid; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (1H-tetrazol-5-ylmethyl)-amide; [(1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-acetic acid; 3-[(1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-propionic acid; 1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-acetylamino-ethyl)-amide; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-acetylamino-ethyl)-amide; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid [2-(methanesulfonyl-methyl-amino)-ethyl]-amide; 1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide; 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide; and 3-[(1-benzyl-8-hydroxy-5-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-propionic acid; or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer, or prodrug thereof.
25. A pharmaceutical composition comprising one or more compounds of claim 3 and a pharmaceutically acceptable excipient.
26. The composition of claim 25 , further comprising at least one additional therapeutic agent selected from the group consisting of vitamin B12, folic acid, ferrous sulfate, recombinant human erythropoietin, and an erythropoiesis stimulating agent (ESA).
27. A method of treating, pretreating, or delaying onset of anemia, the method comprising administering to a patient a therapeutically effective amount of a composition of claim 25 .
28. A method of inhibiting the activity of a HIF hydroxylase, the method comprising bringing into contact the HIF hydroxylase and an inhibitory-effective amount of a compound of claim 3 .
29. The method of claim 28 , wherein the HIF hydroxylase enzyme is an asparaginyl hydroxylase.
30. The method of claim 29 , wherein the asparaginyl hydroxylase is factor inhibiting HIF.
31. The method of claim 28 , wherein the HIF hydroxylase enzyme is a prolyl hydroxylase.
32. The method of claim 31 , wherein the prolyl hydroxylase is selected from the group consisting of human EGLN1, EGLN2, and EGLN3.